API
< Back to all clusters
[HEALTH] · India · 11 sources

started · updated

India implements price cuts for 1,364 anti-cancer drugs

The Indian government has implemented revised Maximum Retail Prices (MRPs) for 1,364 anti-cancer drug formulations, effective November 9, 2026. This move follows a decision by the National Pharmaceutical Pricing Authority (NPPA) to cap trade margins on 137 specific anti-cancer drugs, a measure expected to save consumers approximately Rs 3,540 crore annually.

According to the Ministry of Chemicals and Fertilizers, 85 pharmaceutical companies have reported revised prices covering 121 drugs. Notably, 679 brands have seen price reductions exceeding 50 percent, with the most significant single reduction reaching 96.45 percent. For example, the cost of the breast cancer treatment capsule ‘Palpro’ reportedly dropped from Rs 40,421.33 to Rs 2,720.

To ensure compliance, officials in Andhra Pradesh and other regions have been directed to monitor hospitals and pharmacies to prevent hoarding, artificial shortages, or overcharging. Drug inspectors have been tasked with verifying price implementation within seven days. Consumers can verify current rates via the ‘Pharma Sahi Daam’ mobile application or the NPPA website, and may report overcharging through the Pharma Jan Samadhan portal or a dedicated helpline.

Entities

Department of Pharmaceuticals · Directorate General of Health Services · India · Ministry of Chemicals and Fertilizers · National Pharmaceutical Pricing Authority · Y Satya Kumar Yadav